Good-risk versus poor-risk MRD-positive patients

myelomaMinBannerTemplateNewV1.png

| INNOVATION | Latest Research

490x245MMcells.png

Black Swan researchers identify good-risk and poor-risk MRD patients, China’s ‘disruptive’ biotech, and reasons to eat ‘real food’

IMF Chairman Dr. Brian G.M. Durie spotlights good news for myeloma patients this week: a study funded by the IMF Black Swan Research Initiative demonstrates important differences between patients with good-risk versus poor-risk MRD-positive disease; CAR T speeds ahead in China; and the publication of a shopper’s guide to pesticide-free food.

LearnMoreButton.png

| EMPOWERMENT | Fundraiser

Myeloma5k200v1.png

| EDUCATION | Event

SeattleRCW200x200.png

10th Annual Miles for Myeloma

RCW in Seattle, WA

The 2018 Miles for Myeloma 5K Walk/Run takes place on Saturday, April 28, 2018, at 8:30 a.m. ET at the Memorial Hall/Please Touch Museum (43 Concourse Dr.) in Philadelphia. Help the Philadelphia Multiple Myeloma Networking Group reach their goal of $100,000 by registering or donating today. All proceeds will benefit the IMF’s research initiatives and patient support programs.

The IMF will host a Regional Community Workshop in Seattle on Saturday, May 12, 2018. Registration is FREE, but seating is limited. Here’s your chance to learn from and meet one-on-one with myeloma experts Edward Libby, MD (Seattle Cancer Care Alliance, Seattle, WA), Damian Green, MD (Seattle Cancer Care Alliance, Seattle, WA), Andrew Cowan, MD (Seattle Cancer Care Alliance, Seattle, WA), and Bill Bensinger, MD (Swedish Cancer Institute, Seattle, WA).

registerNowButton.png

registerNowButton.png

| INNOVATION | Drug Approval

490x245Pills.png

Selinexor Receives FDA Fast Track Designation for Patients with Penta-Refractory Myeloma

The U.S. Food and Drug Administration (FDA) this week granted Fast Track designation to Karyopharm’s selinexor, an oral Selective Inhibitor of Nuclear Export (SINE) compound for the treatment of myeloma patients who have received at least three prior lines of therapy. IMF Chairman Dr. Brian G.M. Durie explains how the drug works: “By binding with a protein called XPO1, selinexor blocks the export and, thus, leads to the accumulation of tumor suppressor proteins in the nucleus of myeloma cells."

LearnMoreButton.png

| INNOVATION | Drug Approval

490x245xray.png

European Commissions Expands Indication for Xgeva (denosumab)

The European Commission (EC) has approved an “expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events in adults with advanced malignancies involving bone.” Now covered are patients with bone metastases, including those with solid tumors and/or multiple myeloma. The approval resulted from a phase III ‘482 study, which was “the largest international trial ever conducted for the prevention of skeletal-related events in multiple myeloma patients.”

LearnMoreButton.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox4.12.18.png

CLINICAL TRIALS

EVENTS

BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

April 21, 2018
IMF Regional Community Workshop
Nashville, TN

April 28, 2018
Miles for Myeloma 5K Walk/Run
Philadelphia, PA

May 5-6, 2018
Miracles Happen When Pigs Fly!
Cincinnati, OH

May 12, 2018
IMF Regional Community Workshop
Seattle, WA

June 2, 2018
11th Annual Carolyn Czerkies Memorial Golf Outing
Joliet, IL

 

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year

Research Funding Available